Original ArticlesSequential interferon-α2b, interleukin-2 and fotemustine for patients with metastatic melanomaTerheyden, P.; Becker, J. C.*; Kämpgen, E.; Bröcker, E. -B.Author Information University Department of Dermatology, University of Würzburg, Josef Schneider Str. 2, D-97080 Würzburg, Germany. Tel: (+49) 931 201 5396; Fax: (+49) 931 201 2700; Email: [email protected] *To whom correspondence should be addressed Received 17 January 2000; accepted in revised form 9 May 200 Melanoma Research: October 2000 - Volume 10 - Issue 5 - p 475-482 Buy Abstract The aim of this study was the evaluation of both the antitumour activity and toxicity of an immunochemotherapeutic regimen consisting of interferon-α2b and interleu-kin-2 in combination with fotemustine for patients with metastatic melanoma. To improve the penetration of fotemustine into the brain, it was given immediately after immunotherapy, when the blood-brain barrier is still disturbed. Of the 19 patients treated, three complete remissions (CRs) and one partial remission (PR) were induced, giving an objective response rate of 21% (95% confidence interval 6–46%). The durations of the CRs were 9, 19 and 44 months; the PR lasted for 59+ months. The overall survival times for the patients with CR were 21, 25 and 70+ months, and 59+ months for the PR. For nine patients (47%, 95% confidence interval 24–71%) disease was stabilized for a median period of 8 months (range 2–18 months), resulting in a median survival of 18 months (range 10–41+ months). No haematological toxicity of World Health Organization grade 3 or more was observed and in general toxicity was low. In summary, this immunochemotherapy regimen led to long-term survival in occasional patients, and about half of the patients achieved stable disease, with prolonged treatment- and progression-free survival compared with non-responding patients. The occurrence of brain metastases, however, was not prevented, and in fact was the site of recurrence in those patients achieving a CR. Due to its low toxicity, this protocol can be applied at a community hospital level. © 2000 Lippincott Williams & Wilkins, Inc.